MaxCyte, Inc. MXCT

Company Overview

MaxCyte, Inc. is a cell-engineering and life sciences technology company focused on enabling the development and commercialization of advanced cell-based therapies. The company operates primarily within the biotechnology and cell therapy industries, providing proprietary electroporation technology platforms and related services used in cell and gene therapy development, biologics discovery, and therapeutic manufacturing. Its core revenue drivers include sales and leases of its ExPERT instrument platforms, consumable processing assemblies, and strategic platform licenses tied to clinical and commercial programs.

The company serves biotechnology companies, pharmaceutical manufacturers, academic research institutions, and cell therapy developers globally. MaxCyte’s technology is positioned around non-viral cell engineering, which is viewed by many developers as a scalable alternative to viral-vector approaches for certain applications. Founded in 1998 and headquartered in Rockville, Maryland, MaxCyte evolved from an electroporation-focused research company into a commercial platform provider supporting engineered cell therapy programs, including CAR-T, TCR, stem cell, and gene-editing applications. Its growth has been supported by long-term strategic platform licenses with major biotechnology and pharmaceutical partners.